Loading clinical trials...
Loading clinical trials...
A Phase 1 Two-way Cross-over Study of the Pharmacokinetics and Pharmacodynamics of Crystalline PX-866 Tablets and Amorphous PX-866 Capsules Administered in the Fasting State, and of Crystalline PX-866 Tablets Administered Fed and Fasting, in Healthy Subjects
Conditions
Interventions
PX-866
Locations
1
United States
Comprehensive Clinical Development NW
Tacoma, Washington, United States
Start Date
July 1, 2011
Primary Completion Date
October 1, 2011
Completion Date
January 1, 2012
Last Updated
May 17, 2018
NCT07310264
NCT00090662
NCT06342713
NCT06223555
NCT07472361
NCT01266577
Lead Sponsor
Cascadian Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions